Elamipretide (SS-31): What FDA Approval Means

Elamipretide, also known as SS-31, is unusual among peptides discussed online because it has crossed from experimental research into an FDA approved medicine. That statement needs a boundary around it. The approval is for a rare mitochondrial disease called Barth syndrome, it was granted through the accelerated approval pathway, and it is based on an intermediate measure of muscle strength rather than proof across the many conditions in which SS-31 has been studied.

That makes elamipretide a useful example of how mechanism, human trials and regulatory decisions can point in different directions without actually contradicting each other. The peptide has a clear mitochondrial target, a genuine US approval and years of human research. It also has failed primary endpoints in several controlled trials.

What is elamipretide?

Elamipretide is a synthetic tetrapeptide, meaning it is built from four amino acid residues. It is also known in the research literature as SS-31 and MTP-131. The FDA prescribing information describes it as a mitochondrial cardiolipin binder that localises to the inner mitochondrial membrane and improves mitochondrial morphology and function Mechanistic Regulator approved indication ¹.

Cardiolipin is a phospholipid concentrated in the inner mitochondrial membrane. It helps organise the membrane environment in which the respiratory chain produces much of the cell's usable energy. Barth syndrome is caused by pathogenic variants affecting tafazzin, which disrupt normal cardiolipin remodelling and mitochondrial function Mechanistic ².

The mechanism gives elamipretide a plausible biological target in Barth syndrome. It does not prove clinical benefit by itself. That question has to come from human studies.

What did the FDA actually approve?

On 19 September 2025, the FDA granted accelerated approval to Forzinity, which contains elamipretide, to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg Regulator approved indication ³.

The approval is narrow in three ways.

First, it is for Barth syndrome, not for general fatigue, healthy ageing, exercise performance or a broad category of mitochondrial dysfunction.

Second, it was granted under accelerated approval. The FDA used an intermediate clinical endpoint, knee extensor muscle strength, that it considered reasonably likely to predict patient benefit. The agency requires a confirmatory randomised trial after approval to test whether the strength change translates into a clinical benefit that patients can feel or use in daily life.

Third, the supporting efficacy population was tiny because Barth syndrome is extremely rare. The FDA Drug Trials Snapshot describes 12 male participants aged 12 to 35 in the key study Human ⁴.

An FDA approval therefore answers a specific regulatory question. It does not turn every proposed use of SS-31 into an approved or proven use.

What did the Barth syndrome trial show?

The main human study was TAZPOWER, registered as NCT03098797. It was a randomised, double blind, placebo controlled crossover trial followed by an open label extension in people with genetically confirmed Barth syndrome Human ².

Twelve participants entered the controlled phase. The two original primary endpoints were the six minute walk test and a Barth syndrome symptom assessment focused on fatigue. Neither primary endpoint was met during the blinded crossover portion.

Ten participants continued into the open label extension, and eight had reached 36 weeks when the published analysis was reported. At that point, the six minute walk distance had improved by 95.9 metres from baseline, with a reported p value of 0.024. The symptom assessment improved by 2.1 points, with a reported p value of 0.031 Human ².

Those extension results are encouraging, but they are harder to interpret than a controlled comparison. Every participant in the extension knew they were receiving active treatment, there was no concurrent placebo group, and only a small number remained in the analysis.

The FDA Drug Trials Snapshot makes the distinction clear. It says a significant difference in muscle strength was not shown during the initial 12 week randomised period. The increases in knee extensor strength appeared during the longer open label follow up, and that intermediate endpoint became the basis for accelerated approval Human Regulator approved indication ⁴.

How can a drug be approved when the original primary endpoints were negative?

Accelerated approval is designed for serious conditions with unmet need when an endpoint is considered reasonably likely to predict clinical benefit. It allows the FDA to act before the final clinical benefit has been confirmed, while making continued approval dependent on further evidence.

For elamipretide, the agency accepted improvement in knee extensor muscle strength as that intermediate endpoint. The FDA explicitly states that a confirmatory randomised, double blind, placebo controlled trial is required after approval Regulator approved indication ³.

That is different from saying the failed endpoints no longer matter. They are part of the evidence record. The regulatory decision reflects the whole context: an ultra rare, serious disease, no previous approved treatment, a biologically relevant target, a very small available patient population and an intermediate endpoint that the FDA judged capable of supporting accelerated approval.

The cleanest reading is that elamipretide has a real but conditional regulatory success in Barth syndrome, with confirmation still required.

What happened in larger mitochondrial disease trials?

The wider human evidence is mixed and often negative.

MMPOWER-3 was a phase 3 randomised, double blind, placebo controlled trial in 218 people with genetically confirmed primary mitochondrial myopathy. Participants were followed for 24 weeks. The study had two primary endpoints: change in the six minute walk test and change in a validated fatigue score Human ⁵.

Neither primary endpoint was met. The difference between elamipretide and placebo for the six minute walk test was minus 3.2 metres, with a 95% confidence interval from minus 18.7 to 12.3 metres and a p value of 0.69. The fatigue endpoint was also not significantly different from placebo.

That trial matters because it was much larger than TAZPOWER and tested a broader primary mitochondrial myopathy population. Its negative result does not cancel the Barth syndrome approval, because the diseases and regulatory questions are different. It does show why an approved Barth syndrome indication should not be expanded into a general claim that SS-31 improves mitochondrial disease in humans.

What about eye disease research?

Elamipretide has also been studied in dry age related macular degeneration with geographic atrophy.

ReCLAIM-2 was a randomised, double masked, placebo controlled phase 2 trial in 176 people aged 55 or older. The study ran for 48 weeks and tested visual function and geographic atrophy outcomes Human ⁶.

The trial did not meet either of its primary efficacy endpoints. It did report signals in secondary anatomical measures, including slower progression of ellipsoid zone loss, but those findings do not convert the study into a positive primary endpoint trial.

This distinction matters when reading claims that elamipretide has been "shown to work" across ageing or eye disease. A mechanistic signal, a secondary endpoint and an approved indication are three different levels of evidence.

What does the laboratory evidence show?

The mechanism has been studied in cell systems and model membranes.

In vitro work found that SS-31 partitions into the membrane interface and changes properties linked to surface charge and lipid packing. The authors proposed several ways these membrane effects could influence mitochondrial function, while also making clear that the detailed mechanism remained under study In vitro Mechanistic ⁷.

Earlier work also reported interactions between SS-31 and cardiolipin in experimental mitochondrial systems, with effects on electron transport and energy production under stress In vitro Mechanistic ⁸.

These experiments help explain why a cardiolipin binding peptide was pursued in mitochondrial disease. They do not tell us how much benefit a person will experience.

What does the animal evidence show?

Animal studies add another layer, but they remain preclinical evidence.

In a rat model of cardiac ischemia and reperfusion, elamipretide was associated with better preservation of mitochondrial cristae structure and changes consistent with improved mitochondrial function Animal ⁹.

A 2026 study in a mouse model of mitochondrial trifunctional protein deficiency also reported improved exercise endurance and some mitochondrial enzyme measures, while other outcomes did not change. Patient derived fibroblasts in the same study showed possible genotype dependent bioenergetic effects Animal In vitro ¹⁰.

Animal and cell findings can support a mechanism and help choose what to test next. They cannot replace controlled human outcomes.

What are the main safety findings?

The FDA prescribing information and Drug Trials Snapshot identify injection site reactions as common adverse effects. In the 12 participant controlled Barth syndrome study, all elamipretide treated participants had some form of local administration or injection site reaction, although the individual reaction types varied Human Regulator approved indication ⁴.

The prescribing information also warns about hypersensitivity reactions, including serious reactions in some patients Regulator approved indication ¹.

Safety data from an approved use should still be read in the population and setting in which the medicine was studied. They do not establish the safety of unapproved uses.

What is the UK position in 2026?

The UK record is developing, but it should not be confused with the US approval.

The MHRA has a paediatric investigation plan record for elamipretide in Barth syndrome. The record lists the active substance as elamipretide, the proposed route as subcutaneous use and the invented name as "Not available at present". It also records a compliance opinion dated 24 July 2026 ¹¹.

A paediatric investigation plan is part of medicine development and regulatory planning. It is not a UK marketing authorisation.

The MHRA directs healthcare professionals and the public to its product information service for current UK marketing authorisation records and approved product information ¹².

BioRx therefore does not treat the FDA approval or the UK paediatric investigation plan as proof of a UK approved indication.

What does the evidence support today?

Elamipretide has stronger human and regulatory evidence than many peptides marketed online, but its strongest claim is also its narrowest one.

The FDA has granted accelerated approval for a Barth syndrome indication based on an intermediate muscle strength endpoint. The controlled portion of the small key study did not meet its original walking or fatigue endpoints, while open label follow up showed improvements that helped support the regulatory case. A confirmatory randomised trial is required.

Outside Barth syndrome, the evidence is less supportive. A 218 participant phase 3 trial in primary mitochondrial myopathy missed both primary endpoints. A 176 participant phase 2 trial in geographic atrophy also missed both primary efficacy endpoints, despite secondary signals.

Mechanistic, cell and animal research remains scientifically useful, especially around cardiolipin and mitochondrial membrane structure. It should stay in its own evidence category rather than being used as a shortcut to broad human claims.

For a direct comparison with another mitochondrial peptide, see SS-31 vs MOTS-c. The broader MOTS-c evidence review shows how different the human evidence can be even when two compounds are placed in the same online category.

Frequently asked questions

Is SS-31 the same as elamipretide?

Yes. SS-31 is a research name for elamipretide. The FDA approved product contains elamipretide and is marketed in the United States as Forzinity Regulator approved indication.

Is elamipretide FDA approved?

Yes, for a narrow indication. The FDA granted accelerated approval in September 2025 to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Continued approval requires confirmatory evidence.

Did the main Barth syndrome trial meet its primary endpoints?

No. The randomised crossover portion did not meet its primary six minute walk or fatigue endpoints. Improvements were later reported during the open label extension.

Has elamipretide worked in larger phase 3 trials?

Not consistently. MMPOWER-3 enrolled 218 people with primary mitochondrial myopathy and did not meet either of its primary endpoints at 24 weeks Human.

Does FDA approval prove SS-31 works for healthy ageing or exercise performance?

No. The approved claim is for Barth syndrome and muscle strength. Cell studies, animal studies and trials in other diseases do not establish a general anti ageing or performance benefit in people.

Is elamipretide approved in the UK?

The MHRA record reviewed here is a paediatric investigation plan for Barth syndrome, not a marketing authorisation. UK approval should be checked through the MHRA product information service rather than inferred from the US FDA decision.

References

Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.

Elamipretide (SS-31): What Does FDA Approval Actually Mean?